vs
Side-by-side financial comparison of Ameris Bancorp (ABCB) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Ameris Bancorp is the larger business by last-quarter revenue ($314.4M vs $196.9M, roughly 1.6× Pacira BioSciences, Inc.). On growth, Ameris Bancorp posted the faster year-over-year revenue change (10.0% vs 5.1%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 2.3%).
Ameris Bancorp is an American bank holding company headquartered in Atlanta, Georgia. Through its bank subsidiary, Ameris Bank, the company operates full-service branches in Georgia, Alabama, Florida, North Carolina and South Carolina, and mortgage-only locations in Georgia, Alabama, Florida, North Carolina, South Carolina, Virginia, Maryland, and Tennessee. The company offers online and mobile banking options for both consumers and businesses.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ABCB vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $314.4M | $196.9M |
| Net Profit | $110.5M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | — | 1.2% |
| Net Margin | 35.1% | — |
| Revenue YoY | 10.0% | 5.1% |
| Net Profit YoY | 2.0% | — |
| EPS (diluted) | $1.63 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $314.4M | — | ||
| Q4 25 | $307.1M | $196.9M | ||
| Q3 25 | $314.2M | $179.5M | ||
| Q2 25 | $300.7M | $181.1M | ||
| Q1 25 | $285.9M | $168.9M | ||
| Q4 24 | $290.8M | $187.3M | ||
| Q3 24 | $283.8M | $168.6M | ||
| Q2 24 | $300.6M | $178.0M |
| Q1 26 | $110.5M | — | ||
| Q4 25 | $108.4M | — | ||
| Q3 25 | $106.0M | $5.4M | ||
| Q2 25 | $109.8M | $-4.8M | ||
| Q1 25 | $87.9M | $4.8M | ||
| Q4 24 | $94.4M | — | ||
| Q3 24 | $99.2M | $-143.5M | ||
| Q2 24 | $90.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | 1.2% | ||
| Q3 25 | 43.6% | 3.5% | ||
| Q2 25 | 47.4% | 4.7% | ||
| Q1 25 | 39.5% | 1.2% | ||
| Q4 24 | 43.3% | 13.2% | ||
| Q3 24 | 44.4% | -82.8% | ||
| Q2 24 | 42.1% | 15.9% |
| Q1 26 | 35.1% | — | ||
| Q4 25 | 44.2% | — | ||
| Q3 25 | 33.7% | 3.0% | ||
| Q2 25 | 36.5% | -2.7% | ||
| Q1 25 | 30.8% | 2.8% | ||
| Q4 24 | 42.5% | — | ||
| Q3 24 | 35.0% | -85.1% | ||
| Q2 24 | 30.2% | 10.6% |
| Q1 26 | $1.63 | — | ||
| Q4 25 | $1.59 | $0.05 | ||
| Q3 25 | $1.54 | $0.12 | ||
| Q2 25 | $1.60 | $-0.11 | ||
| Q1 25 | $1.27 | $0.10 | ||
| Q4 24 | $1.35 | $0.38 | ||
| Q3 24 | $1.44 | $-3.11 | ||
| Q2 24 | $1.32 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $4.1B | $693.1M |
| Total Assets | $28.1B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $4.1B | — | ||
| Q4 25 | $4.1B | $693.1M | ||
| Q3 25 | $4.0B | $727.2M | ||
| Q2 25 | $3.9B | $757.8M | ||
| Q1 25 | $3.8B | $798.5M | ||
| Q4 24 | $3.8B | $778.3M | ||
| Q3 24 | $3.7B | $749.6M | ||
| Q2 24 | $3.6B | $879.3M |
| Q1 26 | $28.1B | — | ||
| Q4 25 | $27.5B | $1.3B | ||
| Q3 25 | $27.1B | $1.3B | ||
| Q2 25 | $26.7B | $1.5B | ||
| Q1 25 | $26.5B | $1.6B | ||
| Q4 24 | $26.3B | $1.6B | ||
| Q3 24 | $26.4B | $1.5B | ||
| Q2 24 | $26.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $43.7M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 22.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $390.2M | $43.7M | ||
| Q3 25 | $104.9M | $60.8M | ||
| Q2 25 | $61.4M | $12.0M | ||
| Q1 25 | $116.9M | $35.5M | ||
| Q4 24 | $154.2M | $33.1M | ||
| Q3 24 | $102.2M | $53.9M | ||
| Q2 24 | $-97.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $369.6M | $43.5M | ||
| Q3 25 | $100.5M | $57.0M | ||
| Q2 25 | $53.7M | $9.3M | ||
| Q1 25 | $114.2M | $26.9M | ||
| Q4 24 | $140.7M | $31.0M | ||
| Q3 24 | $99.8M | $49.8M | ||
| Q2 24 | $-100.3M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 120.4% | 22.1% | ||
| Q3 25 | 32.0% | 31.7% | ||
| Q2 25 | 17.9% | 5.1% | ||
| Q1 25 | 39.9% | 15.9% | ||
| Q4 24 | 48.4% | 16.6% | ||
| Q3 24 | 35.2% | 29.6% | ||
| Q2 24 | -33.4% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 0.1% | ||
| Q3 25 | 1.4% | 2.2% | ||
| Q2 25 | 2.5% | 1.5% | ||
| Q1 25 | 0.9% | 5.1% | ||
| Q4 24 | 4.6% | 1.1% | ||
| Q3 24 | 0.8% | 2.4% | ||
| Q2 24 | 1.1% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.60× | — | ||
| Q3 25 | 0.99× | 11.20× | ||
| Q2 25 | 0.56× | — | ||
| Q1 25 | 1.33× | 7.37× | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | -1.07× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCB
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
